Table 3.

Details of other excluded non-RCTs

Study name	Study details
Ach 2007	Prospective case series of bevacizumab for mixed pathologies including RVO-ME (n = 3) but no data on CRVO-ME specifically
Byeon 2007	Retrospective case series of bevacizumab for mixed pathologies including RVO-ME, of which n = 3 CRVO-ME, but no data on CRVO-ME specifically
Kriechbaum 2009	Prospective case series of bevacizumab for n= 28 patients with RVO-ME, to investigate the association between functional and anatomical retinal changes using microperimetry and spectral domain OCT. Data specific to CRVO-ME not reported
Rosenfeld 2005	Case report of bevacizumab for CRVO-ME in a patient previously treated with IVTA
Sakamoto 2009	Prospective case series of bevacizumab for n = 31 with RVO-ME, including n = 14 with CRVO-ME. Data specific to CRVO-ME not reported
Shetty 2008	Prospective case series of bevacizumab for mixed etiologies of ME, of which n = 5 with CRVO-ME, but no data on CRVO-ME specifically
Spaide 2009	Prospective case series of ranibizumab for patients with decreased visual acuity associated with CRVO (i.e. not specific to patients with ME at baseline). n = 11 had prior treatment with bevacizumab, and of these n = 3 also had prior treatment with IVTA. Data for patients with CRVO-ME at baseline and no prior treatment not reported specifically
Wu 2008	Retrospective multicenter case series of bevacizumab given for different indications (n = 1173), reporting 12-month safety data for combined pathologies (of which n = 66 CRVO, but specific data not given)

CRVO: central retinal vein occlusion

IVTA: intravitreal triamcinolone

ME: macular edema

RCT: randomized controlled trial

RVO: retinal vein occlusion